SLC5A2 and type 2 diabetes mellitus: Canagliflozin is an oral sodium–glucose cotransporter-2 (SGLT-2) inhibitor approved by the Food and Drug Administration (FDA) in 2013 to improve glycemic control in patients with type 2 diabetes (T2DM).